The review highlights the importance of maintaining optimal tissue perfusion during antihypertensive therapy to prevent end-organ damage and improve cardiovascular prognosis.
Answers are grounded in this paper and cite their sources.
Perfusion preservation during antihypertensive therapy may reduce end-organ damage; leaves open precise targets for prospective trials.
Experimental and clinical studies have established a link between end-organ damage in hypertensive patients and the severe impairment of tissue perfusion and microcirculation structure and function. Microvascular rarefaction is constantly observed in hypertension, and probably contributes to higher systemic resistance and lower tissue perfusion. Endothelial dysfunction leading to impaired arteriolar reactivity is also characteristic of the microvascular dysfunction in hypertensive patients. The effective lowering of blood pressure while maintaining optimal tissue perfusion is therefore one of the major goals of antihypertensive therapy, in order to improve the cardiovascular prognosis of hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Bernard Lévy (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: